Alzheimer's disease; amyloid b oligomer; ephrin type-B receptor 2 Correspondence
Ephrin type-B receptor 2 (EphB2) is a member of the receptor tyrosine kinase family and plays an important role in learning and memory functions. In patients with Alzheimer's disease (AD) and in mouse models of AD, a reduction in the hippocampal EphB2 level is observed. It was recently reported that normalization of the EphB2 level in the dentate gyrus rescues memory function in a mouse model of AD, suggesting that drugs that restore EphB2 levels may be beneficial in the treatment of AD. Amyloid b (Ab) oligomers, which are believed to be key molecules involved in the pathogenesis of AD, induce EphB2 degradation through their direct binding to EphB2. Thus, compounds that inhibit the binding of Ab oligomers to EphB2 may be beneficial. Here, we screened for such compounds from drugs already approved for clinical use in humans. Utilizing a cellfree screening assay, we determined that dihydroergotamine mesilate, bromocriptine mesilate, cepharanthine, and levonorgestrel inhibited the binding of Ab oligomers to EphB2 but not to cellular prion protein, another endogenous receptor for Ab oligomers. Additionally, these four compounds did not affect the binding between EphB2 and ephrinB2, an endogenous ligand for EphB2, suggesting that the compounds selectively inhibited the binding of Ab oligomers to EphB2. This is the first identification of compounds that selectively inhibit the binding of Ab oligomers to EphB2. These results suggest that these four compounds may be safe and effective drugs for treatment of AD.
Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most common cause of dementia. Because the world's population is aging, the number of AD patients has been increasing; however, there are currently no disease-modifying treatments for AD. Thus, development of disease-modifying drugs is important.
One hallmark pathological feature of AD is senile plaques, which are composed of amyloid b peptide (Ab). Monomeric Ab easily self-assembles to form soluble oligomers, protofibrils, and fibrils. A correlation between the amount of soluble Ab oligomers and cognitive impairment in AD patients has been reported [1] . In addition, soluble Ab oligomers inhibit long-term potentiation (LTP) [2, 3] which is involved in learning and memory functions [4] . Therefore, Ab oligomers are believed to play an important role in the learning and memory dysfunction observed in patients with AD.
Some endogenous receptors for Ab oligomers, such as ephrin type-B receptor 2 (EphB2) and cellular prion protein (PrP C ), appear to be involved in the inhibitory effects of Ab oligomers on LTP [5] [6] [7] . EphB2, a member of the receptor tyrosine kinase family [8] , is a receptor for ephrinB ligands (B1, B2, and B3) and ephrinA5 [9] and functions in synaptic plasticity and synapse formation [10] [11] [12] . Mice lacking EphB2 exhibit LTP impairment and memory dysfunction [11, 12] . Reduced EphB2 levels are observed in postmortem hippocampal tissue from patients with AD [13] and in mouse models of AD [5, 13, 14] . Ab oligomers directly bind to EphB2 and induce its internalization and proteasome-mediated degradation [5] . In addition, artificial expression of EphB2 in the dentate gyrus rescues LTP and memory function in a mouse model of AD [5] . These results suggest that inhibiting Ab oligomer binding to EphB2 may be therapeutically beneficial in the treatment of AD.
The number of drugs reaching the marketplace each year is decreasing, mainly due to unexpected adverse effects being revealed at advanced stages of clinical trials. To overcome this problem, we took advantage of a recent strategy for drug discovery and development that focuses on examining drugs already approved for use in humans (i.e., drug repositioning). In this strategy, compounds with clinically beneficial pharmacological activity are screened from a library of approved drugs already in clinical use to be developed for new indications. One major advantage of this strategy is a decreased risk for unexpected adverse effects in humans because the safety of these drugs has already been well characterized in humans [15] .
In the present study, from a library of approved drugs already in clinical use, we screened for compounds that inhibited the binding of Ab oligomers to EphB2. We identified dihydroergotamine mesilate (DIH), bromocriptine mesilate (BRO), cepharanthine (CEP), and levonorgestrel (LEV). Although these compounds inhibited the binding of Ab oligomers to EphB2, they did not inhibit the binding of an endogenous ligand, ephrinB2, to EphB2. This is the first time that compounds that selectively inhibited the binding of Ab oligomers to EphB2 have been identified. 
Materials and methods

Materials
Ab monomer and oligomer preparation
Ab monomers and oligomers were prepared as described previously [16] . Biotin-Ab was dissolved in HFIP and incubated at room temperature for 1 h and then on ice for 10 min. The HFIP was evaporated and the peptides were dissolved in DMSO for a final concentration of 10 mM. The peptides were diluted in phenol red-free DMEM to give a final concentration of 100 lM and subjected to sonication (AIWA Co., Tokyo, Japan) for 10 min. For oligomer preparation, the Ab solution described above was incubated at 37°C for 16 h and then centrifuged at 20 400 g for 15 min. The supernatant was frozen in liquid nitrogen and stored at À80°C until use.
For monomer preparation, the sample was centrifuged and stored in a manner similar to that for oligomer preparation, without the incubation at 37°C for 16 h.
Characterization of Ab oligomers by immunoblotting
To characterize Ab oligomers, the supernatant was mixed with equal amounts of sample buffer and boiled at 98°C for 5 min. Samples were applied to polyacrylamide sodium dodecyl sulfate gels and subjected to electrophoresis, after which proteins were immunoblotted with 6E10.
Cell-free binding assay
The cell-free binding assay was performed as described previously [16] . To evaluate binding between Ab and EphB2, EphB2-Fc was dissolved in phosphate-buffered saline (PBS) to a final concentration of 0. 
To evaluate binding between Ab and PrP C , EphB2-Fc was replaced with His-tagged human PrP C .
To evaluate binding between ephrinB2 and EphB2, biotin-Ab in DMEM was replaced with biotinylated ephrinB2-Fc in PBS (500 ngÁmL À1 ).
Chemical library and screening
Each drug in the library was dissolved in water or DMSO, depending on the drug. The concentration of each drug in the library was 1 mM, 5 mM, 10 mM, 25 mM, 50 mM, 100 mM, 2 mgÁmL À1 , 10 mgÁmL À1 , or 100 mgÁmL 
Statistical analysis
All values are expressed as the mean AE standard deviation (SD). One-way analysis of variance (ANOVA) followed by Tukey's test was used to evaluate differences among three or more groups. Differences were considered statistically significant at P values less than 0.05.
Results and Discussion
Screening of approved drugs for compounds that inhibit the binding of Ab oligomers to EphB2
To screen for inhibitors of Ab oligomer binding to EphB2, we used a cell-free binding assay. In this assay, biotin-Ab was applied to EphB2-coated wells, and after washing, the amount of bound biotin-Ab was determined using HRP-streptavidin. Ab oligomers were prepared by incubation at 37°C for 16 h, and we confirmed the formation of Ab oligomers by immunoblotting (Fig. 1A) .
We first compared the ability of Ab monomers and oligomers to bind EphB2. We found that Ab oligomers bound to EphB2 more efficiently than did the monomers (Fig. 1B) . This result was consistent with a previous report [5] and suggested that this assay was appropriate for screening compounds that inhibited the binding of Ab oligomers to EphB2.
From a library of 840 drugs approved for clinical use, we screened for compounds that inhibited the binding of Ab oligomers to EphB2. Each compound was applied to the cell-free binding assay simultaneously with Ab oligomers, and the amount of bound biotin-Ab was determined (Fig. 1C) . As an assay quality parameter, we calculated Z 0 -factor to be 0.89, Among 52 compounds that inhibited more than 30% of the Ab oligomer binding to EphB2 in the screening, 22 compounds that inhibited more than 30% of the Ab oligomer binding to EphB2 in additional two independent experiments are listed. The effects of these 22 compounds on the binding of Ab oligomers to EphB2 in the screening and in the additional two independent experiments (reproducibility) and on the binding of Ab oligomers to PrP C were shown. The four compounds that inhibited less than 30% of the Ab oligomer binding to PrP supporting the quality of this assay. Among these 840 compounds, 52 compounds inhibited more than 30% of the Ab oligomer binding to EphB2. We examined the effect of these compounds on the binding in additional two independent experiments. We selected 22 compounds that inhibited more than 30% of the Ab oligomer binding to EphB2 in both experiments (Table 1 , red dots in Fig. 1C ). Through this screening procedure, we also found five compounds that enhanced the binding of Ab oligomers to EphB2 to more than 200% (Table 2) .
To select compounds that selectively inhibited the Ab oligomer binding to EphB2, we next examined the effects of these 22 compounds on the binding of Ab oligomers to PrP C . We found four compounds (DIH, BRO, CEP, and LEV; Fig. 2A ) that inhibited less than 30% of the Ab oligomer binding to PrP C ( Table 1 ). As shown in Fig. 2B , each of these four compounds inhibited the binding of Ab oligomers to EphB2 in a concentration-dependent manner. Additionally, under conditions in which an antibody against PrP C (ICSM35) [7] inhibited the binding of Ab oligomers to PrP C , none of these four compounds inhibited the binding (Fig. 2C) . These results suggested that these four compounds selectively inhibited the binding of Ab oligomers to EphB2.
Effects of selected compounds on the binding of ephrinB2 to EphB2
The results in Fig. 2 suggested that the four selected compounds interacted with EphB2 rather than with Ab oligomers to inhibit their binding. Thus, it is possible that these compounds may inhibit the binding between EphB2 and its endogenous ligands, which may cause adverse clinical effects. Thus, we examined the effects of these four compounds on the binding of one of the endogenous ligands, ephrinB2, to EphB2. As shown in Fig. 3 , none of these four compounds inhibited the binding of ephrinB2 to EphB2. We confirmed the inhibitory effect of lithocholic acid, which interferes with Eph-ephrin interactions [18] , on the binding of ephrinB2 to EphB2 (Fig. 3) .
Recently, some compounds were reported to inhibit the binding of Ab to its receptors. For example, Deane et al. [19] identified FPS-ZM1 as an inhibitor for the binding of Ab to the receptor for advanced glycation end products, and Risse et al. identified Chicago Sky Blue 6B as an inhibitor for the binding of Ab to PrP C [20] . Furthermore, Fu et al. reported that rhynchophylline binds to EphA4 and stimulated LTP in the presence of Ab oligomer [21] .
As described above, Ab oligomers directly bind to EphB2 and induce its degradation, resulting in LTP impairment and memory dysfunction [5] . Because artificial induction of EphB2 expression in the dentate gyrus rescues LTP and memory function in a mouse model of AD [5] , induction of EphB2 expression is a potential drug target for treatment of AD. However, EphB2 is also involved in the development of cancer [22, 23] and may stimulate cancer progression. Thus, inhibiting the binding between Ab oligomers and EphB2 is a better target for developing drugs aimed at AD treatment. Here, we found 22 compounds with such activity. Among them, 18 compounds also inhibited the binding of Ab oligomers to PrP C , whereas four compounds did not. Although we focused on the latter group for development of AD therapeutics, the former group is also interesting. In addition to EphB2, other receptors for Ab oligomers, such as PrP C [6, 7, 24] , leukocyte immunoglobulin-like receptor B2 [25] , and IgG Fcc receptor II-b [26] , are involved in the inhibitory effect on LTP and in neurotoxicity.
Therefore, compounds that inhibit the binding of Ab oligomers to various receptors may have beneficial effects for treatment of patients with AD. Indeed, among the 18 compounds identified here, montelukast [27] , minocycline [28, 29] , and bexarotene [30] reportedly have beneficial effects in animal models of AD.
The four compounds we identified that selectively inhibited the binding of Ab oligomers to EphB2 (DIH, BRO, CEP, and LEV) are approved for use in humans as treatments for migraine, Parkinson's disease, and leucopenia, as well as for use as a contraceptive, respectively. Among these compounds, DIH, BRO, and CEP penetrate the blood-brain barrier [31] [32] [33] . Thus, our results suggest that these compounds, especially DIH, BRO, and CEP, may be safe and effective drugs for treatment of AD. On the other hand, these compounds required relatively high concentration to show their inhibitory effect on the binding of Ab oligomers to EphB2. Therefore, we also consider the drug modification, using these approved medicines as leads.
As described above, the compounds identified in this study are expected to ameliorate Ab oligomer-induced LTP impairment. EphB2 overexpression suppresses Ab oligomer-induced neurotoxicity in cultured hippocampal neurons [34] , and activation of EphB2 attenuates tau phosphorylation in a mouse model of AD [35] . Because both Ab oligomer-induced neurotoxicity and tau phosphorylation are important factors in AD pathology, the four compounds identified here may also prove useful for AD treatment through these mechanisms.
In conclusion, we screened for compounds that selectively inhibit the binding of Ab oligomers to EphB2 from a library of approved drugs already in clinical use, and identified dihydroergotamine mesilate, bromocriptine mesilate, cepharanthine, and levonorgestrel. We propose further analysis of these compounds as candidates for AD treatment.
